$165.13 Million in Sales Expected for Seattle Genetics, Inc. (SGEN) This Quarter

Wall Street analysts forecast that Seattle Genetics, Inc. (NASDAQ:SGEN) will post sales of $165.13 million for the current fiscal quarter, according to Zacks. Six analysts have made estimates for Seattle Genetics’ earnings, with the lowest sales estimate coming in at $163.00 million and the highest estimate coming in at $166.89 million. Seattle Genetics posted sales of $129.61 million during the same quarter last year, which suggests a positive year over year growth rate of 27.4%. The firm is scheduled to report its next earnings report on Tuesday, February 5th.

On average, analysts expect that Seattle Genetics will report full-year sales of $645.20 million for the current year, with estimates ranging from $643.00 million to $647.08 million. For the next financial year, analysts anticipate that the firm will post sales of $850.10 million, with estimates ranging from $810.40 million to $927.10 million. Zacks’ sales calculations are an average based on a survey of research firms that that provide coverage for Seattle Genetics.

Seattle Genetics (NASDAQ:SGEN) last posted its earnings results on Thursday, October 25th. The biotechnology company reported ($0.42) EPS for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.15). The business had revenue of $169.42 million for the quarter, compared to analysts’ expectations of $164.75 million. Seattle Genetics had a negative net margin of 26.58% and a negative return on equity of 19.13%.

A number of research firms have commented on SGEN. Cann reissued a “hold” rating on shares of Seattle Genetics in a research report on Monday, October 1st. TheStreet downgraded shares of Seattle Genetics from a “c” rating to a “d+” rating in a research report on Thursday, October 25th. BidaskClub downgraded shares of Seattle Genetics from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, October 9th. Piper Jaffray Companies cut their target price on shares of Seattle Genetics to $66.00 and set a “neutral” rating on the stock in a research report on Thursday, October 25th. Finally, JPMorgan Chase & Co. reissued a “buy” rating and set a $85.00 target price on shares of Seattle Genetics in a research report on Wednesday, September 26th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the stock. Seattle Genetics currently has a consensus rating of “Buy” and an average target price of $77.77.

In other news, insider Vaughn B. Himes sold 5,000 shares of Seattle Genetics stock in a transaction that occurred on Friday, November 30th. The shares were sold at an average price of $62.14, for a total value of $310,700.00. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Clay B. Siegall sold 20,148 shares of Seattle Genetics stock in a transaction that occurred on Monday, October 8th. The stock was sold at an average price of $77.39, for a total transaction of $1,559,253.72. The disclosure for this sale can be found here. In the last ninety days, insiders sold 76,611 shares of company stock worth $5,334,380. Insiders own 33.80% of the company’s stock.

Institutional investors have recently modified their holdings of the company. Harvest Fund Management Co. Ltd purchased a new position in shares of Seattle Genetics in the 3rd quarter worth approximately $104,000. Paradigm Asset Management Co. LLC purchased a new position in shares of Seattle Genetics in the 3rd quarter worth approximately $108,000. OLD Mutual Customised Solutions Proprietary Ltd. purchased a new position in shares of Seattle Genetics in the 2nd quarter worth approximately $139,000. Glenmede Trust Co. NA grew its position in shares of Seattle Genetics by 500.0% in the 3rd quarter. Glenmede Trust Co. NA now owns 2,400 shares of the biotechnology company’s stock worth $185,000 after buying an additional 2,000 shares during the last quarter. Finally, Hollencrest Capital Management purchased a new position in shares of Seattle Genetics in the 3rd quarter worth approximately $216,000.

NASDAQ SGEN opened at $59.99 on Friday. The stock has a market cap of $9.78 billion, a price-to-earnings ratio of -68.17 and a beta of 2.20. Seattle Genetics has a one year low of $47.75 and a one year high of $84.37.

Seattle Genetics Company Profile

Seattle Genetics, Inc, a biotechnology company, focuses on the development and commercialization of targeted therapies for the treatment of cancer worldwide. It markets ADCETRIS, an antibody-drug conjugate for the treatment of relapsed Hodgkin lymphoma and relapsed systemic anaplastic large cell lymphoma.

Further Reading: What Factors Can Affect Return on Equity?

Get a free copy of the Zacks research report on Seattle Genetics (SGEN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Seattle Genetics (NASDAQ:SGEN)

Receive News & Ratings for Seattle Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seattle Genetics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply